StreetInsider.com News Articles

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

Thu, 22 Oct 2026 18:40:00 -0400

In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD

In participants with CKD, lorundrostat also reduced albuminuria by 52% versus placebo, validating similar findings in a prior trial in participants with established CKD

RADNOR, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

Thu, 22 Oct 2026 18:40:00 -0400

In participants with CKD, lorundrostat also reduced albuminuria by 52% versus placebo, validating similar findings in a prior trial in participants with established CKD

Form 4 Mineralys Therapeutics, For: Oct 19 Filed by: Peterson Kristine

Tue, 20 Oct 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20261020/27211386.html

Form 4 Mineralys Therapeutics, For: Oct 19 Filed by: COATS LONNEL

Tue, 20 Oct 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20261020/27211379.html

Form 3 Mineralys Therapeutics, For: Oct 19 Filed by: Peterson Kristine

Tue, 20 Oct 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20261020/27211381.html

Form 3 Mineralys Therapeutics, For: Oct 19 Filed by: COATS LONNEL

Tue, 20 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261020/27211368.html

Form 8-K Mineralys Therapeutics, For: Oct 16

Mon, 19 Oct 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20261019/27204407.html

Mineralys Therapeutics adds two directors with pharma experience

Mon, 19 Oct 2026 16:05:46 -0400

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has appointed Kristine Peterson and Lonnel Coats to its board of directors, according to a company statement.

Peterson brings more than three decades of biopharmaceutical experience, including roles as chief executive officer of Valeritas, Inc. and Company Group Chair of the Biotechnology Group at Johnson & Johnson, where she led operations in oncology, immunology and cell therapy. She also spent 20 years at Bristol-Myers Squibb, including leading its cardiovascular and metabolic disease business unit. Peterson currently serves on the boards of ArriVent BioPharma, Enanta Pharmaceuticals and Immunocore Holdings.

Coats also has more than three decades of experience

Mineralys Therapeutics adds two directors with pharma experience

Mon, 19 Oct 2026 16:05:46 -0400

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has appointed Kristine Peterson and Lonnel Coats to its board of directors, according to a company statement.

Coats also has more than three decades of experience

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mon, 19 Oct 2026 16:05:00 -0400

RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that Kristine Peterson and Lonnel Coats have been appointed to the Company’s Board of Directors.

“We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension,” stated Jon

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mon, 19 Oct 2026 16:05:00 -0400

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mon, 19 Oct 2026 16:05:00 -0400

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mon, 19 Oct 2026 16:05:00 -0400

Form 144 Mineralys Therapeutics, Filed by: Rodman David Malcom

Tue, 13 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261013/27181217.html

H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Mon, 12 Oct 2026 06:52:33 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $56.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS).

The analyst commented: 'Mineralys Therapeutics presented new data for aldosterone synthase inhibitor (ASI) lorundrostat at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, adding to the clinical evidence supporting lorundrostat’s potential in difficult-to-treat hypertension. We view the latest findings as constructive ahead of the approaching December 22, 2026, PDUFA, supporting lorundrostat’s profile for delivering clinically meaningful BP reductions in patients who remain above target despite multiple standard anti-hypertensive therapies. Importantly, the new Launch-HTN analysis provides a more tangible perspective on the

UBS Starts Mineralys Therapeutics, Inc. (MLYS) at Neutral

Mon, 12 Oct 2026 02:24:10 -0400

UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) with a Neutral rating and a price target of $29.00.

The analyst comments: “We initiate coverage of Mineralys (MLYS) with a Neutral rating, and $29 PT. MLYS's lorundrostat (lor), an aldosterone synthase inhibitor (ASI) for later-line hypertension (HTN), is under FDA review and, if approved, is positioned for a commercial launch in late '26/early '27. We believe lor can become a meaningful product, supported by a large HTN oppy, strong Phase 3 data, and the potential for ASI indication expansion. Nonetheless, in our view, the stock is likely to

UBS Starts Mineralys Therapeutics, Inc. (MLYS) at Neutral

Mon, 12 Oct 2026 02:24:10 -0400

UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) with a Neutral rating and a price target of $29.00.

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Fri, 09 Oct 2026 09:00:00 -0400

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 mmHg at 12 weeks, with more than two-thirds achieving ≥10 mmHg systolic blood pressure reduction -

- In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices -

RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Fri, 09 Oct 2026 09:00:00 -0400

RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.

Form 4 Mineralys Therapeutics, For: Sep 30 Filed by: Congleton Jon

Fri, 02 Oct 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20261002/27143783.html

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Fri, 02 Oct 2026 16:30:00 -0400

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

Oral Presentation Details:

Title:

Blood Pressure

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Fri, 02 Oct 2026 16:30:00 -0400

Oral Presentation Details:

Title:

Blood Pressure

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Thu, 01 Oct 2026 16:05:00 -0400

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA.

Oral Presentation Details:

Title:

Efficacy and Safety of the Selective

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Thu, 01 Oct 2026 16:05:00 -0400

Oral Presentation Details:

Title:

Efficacy and Safety of the Selective

Form 144 Mineralys Therapeutics, Filed by: Congleton Jon

Wed, 30 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260930/27128729.html